Graves’ disease is an autoimmune disorder that affects the thyroid gland. It is the most common form of hyperthyroidism, a condition in which the thyroid gland produces too much of the hormone thyroxine. It is named after Robert J. Graves, an Irish physician who first described the disorder in 1835. The cause of Graves’ disease is unknown, although it is believed to be linked to genetic and environmental factors. Symptoms of Graves’ disease can include weight loss, fatigue, anxiety, irritability, heat intolerance, and an enlarged thyroid gland (goiter). Treatment for Graves’ disease typically involves medications to reduce thyroxine levels and surgery to remove part or all of the thyroid gland.
Graves’ disease is an autoimmune disorder in which the body’s immune system mistakenly attacks the thyroid gland. This causes the thyroid gland to produce too much of the hormone thyroxine. Too much thyroxine can lead to a number of symptoms, including weight loss, fatigue, anxiety, irritability, heat intolerance, and an enlarged thyroid gland (goiter). Graves’ disease is the most common form of hyperthyroidism, and it is estimated to affect approximately 1 in 200 people.
The exact cause of Graves’ disease is unknown, although it is believed to be linked to genetic and environmental factors. Studies have shown that people with Graves’ disease are more likely to have certain genetic variations, which may increase their risk of developing the disorder. Additionally, environmental factors such as stress, smoking, and certain medications may increase the risk of developing Graves’ disease.
Graves’ disease is typically diagnosed based on a physical examination and a review of the patient’s medical history. A doctor may also order blood tests to measure levels of thyroid hormones and antibodies associated with Graves’ disease. An imaging test such as an ultrasound or CT scan may be used to look for an enlarged thyroid gland.
Treatment for Graves’ disease typically involves medications to reduce thyroxine levels and surgery to remove part or all of the thyroid gland. Medications such as antithyroid drugs, beta-blockers, and radioactive iodine can be used to reduce the production of thyroxine. Surgery to remove part or all of the thyroid gland is usually recommended for people with severe symptoms or those who do not respond to medications.
Graves’ disease is an autoimmune disorder that affects the thyroid gland. It is the most common form of hyperthyroidism and it is estimated to affect approximately 1 in 200 people. The cause of Graves’ disease is unknown, although it is believed to be linked to genetic and environmental factors. Treatment for Graves’ disease typically involves medications to reduce thyroxine levels and surgery to remove part or all of the thyroid gland. It is important for doctors to be aware of the signs and symptoms of Graves’ disease in order to properly diagnose and treat the disorder.
1.
Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.
2.
Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.
3.
Long-term study links chronic conditions in midlife to higher cancer risk and mortality
4.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
5.
When does a melanoma metastasize? Implications for management
1.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
2.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
3.
Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025
4.
Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked
5.
Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation